Cisplatin is a potent cytotoxic agent used in the treatment of various malignancies and exerts its antitumor effect through malignant cell DNA damage and apoptosis induction. Evaluation of systemic delivery of cisplatin is important in optimization of cisplatin treatment. However, accurate quantification of systemic cisplatin is challenging due to its various forms in circulation. This study aimed to develop a sensitive (LOQ < 0.1 µg/mL) and precise Ultra Performance Liquid Chromatography (UPLC) - Tandem Mass Spectrometry (MS/MS) method for quantifying free cisplatin in microdialysates and plasma. Furthermore the aim was to compare free cisplatin concentrations measured in standard plasma samples with those obtained from intravenous microdialysis catheters in a porcine model. The method developed utilizes dichloro(ethylenediamine)platinum(II) as an internal standard that co-elutes with cisplatin, ensuring precise correction for ion suppression/enhancement effects. The method was validated, demonstrating linearity up to 100 µg/mL and good intermediate precision (CV% < 6 %) in the range of 1.0-100 µg/mL, with an LOQ of 0.03 µg/mL. The pharmacokinetic parameters (AUC0-last, Cmax, T1/2, and Tmax) showed no significant differences between the two sampling methods. This validated LC-MS/MS method provides a reliable tool for quantifying systemic free cisplatin concentrations, facilitating future systemic and local pharmacokinetic evaluations for optimization of cisplatin-based cancer treatments.
8 February 2024 in Cancer Chemotherapy and Pharmacology
Purpose: Doxorubicin is a widely used chemotherapeutic drug that can be administered intravenously as both a bolus infusion and a continuous infusion. The latter is believed to lower the risk of cardiotoxicity, which is a critical long-term complication of doxorubicin treatment. The local tissue concentrations of doxorubicin will be reflected in both treatment efficacy and toxicity, but very limited information is available. The aim of this study was to measure the concentration of doxorubicin after continuous and bolus infusion in tissue compartments around a typical location of a bone tumour. Methods: Sixteen pigs (female, Danish Landrace, mean weight 77 kg) were randomized into two groups of eight. Both groups received an intravenous infusion of 150 mg doxorubicin; Group 1 received a bolus infusion (10–15 min) and Group 2 received a continuous infusion (6 h). Before infusion, microdialysis catheters were placed intravenously and in four bone tumour-relevant tissue compartments (cancellous bone, subcutaneous tissue, synovial fluid of the knee joint and muscle tissue). Sampling was done (n = 15) over 24 h, and venous blood samples were collected as a reference. Results: Area under the concentration–time curve (AUC0–24 h) for plasma (total concentration) was significantly different between the two groups, while peak drug concentration (Cmax) was significantly higher in two compartments (plasma and synovial fluid of the knee joint) in Group 1 compared to Group 2. Overall, the unbound tissue concentrations were extremely low with values below 0.20 µg/mL. Conclusion: The pharmacokinetic profile for doxorubicin in the investigated tissues is very similar when comparing bolus and 6 h continuous infusion.
Background: This study aimed to establish a feasible large porcine model for dynamic assessment of cisplatin concentrations in carcinomatosis-relevant abdominal tissues using microdialysis during and after HIPEC combined with cytoreductive surgery. Methods: In total, eight pigs underwent open abdominal cytoreductive surgery followed by HIPEC. Microdialysis was employed for dynamic cisplatin concentration sampling in abdominal organs and tissue. Cisplatin dialysate concentrations were analyzed using the UPLC-MS/MS method. STATA (version 18.0) was used to perform a two-compartment model with a zero-order distribution to analyze pharmacokinetic parameters. Results: Detectable cisplatin concentrations in the evaluated target tissues persisted for at least 6 h post-HIPEC. Higher concentrations were found in superficial tissues; however, the difference was not statistically significant. The cisplatin concentrations were comparable for the stomach, rectum, and liver but higher in the peritoneal lining of the abdominal wall, with the lowest median average peak concentration (Cmax) in the rectum (0.50 µg/mL) and the highest median Cmax in the peritoneum (2.80 µg/mL). No statistically significant differences in cisplatin area under the curve from time zero to the time of the last sample collection (AUC0–last) were found between any of the abdominal compartments except the peritoneal lining of the abdominal wall, which was significantly higher compared with most of the other abdominal tissues {smallest difference; peritoneum 1/liver 2; 1.96 [95% confidence interval (CI) 0.90; 4.26, P = 0.09] and largest difference; peritoneum 3/rectum profound; 4.60 [95% CI 1.94; 10.90, P = 0.001]}. Conclusions: Our investigation revealed comparable cisplatin concentrations across abdominal organ surfaces, except higher concentrations in the peritoneal lining of the abdominal wall than in the stomach, rectum, and liver. This model holds promise for future research into HIPEC interventions and anticancer effectiveness.
23 September 2025 in International Journal of Gynecological Cancer
To determine the incidence rate and risk factors associated with the development of diaphragm hernias following left diaphragm procedures at the time of ovarian cancer cytoreduction. We retrospectively reviewed data from patients diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who underwent any timeframe of cytoreductive surgery (primary, interval, secondary, tertiary) at our institution from December 2010 to September 2024. Patients were included if they underwent left diaphragm peritonectomy or resection as part of their cytoreductive surgery. The diagnosis of left diaphragm hernia was made by computed tomography of the chest either as an incidental finding during follow-up surveillance or during work-up for symptomatology. We utilized statistical analysis with descriptive proportions with interquartile ranges. A total of 267 patients with ovarian cancer underwent a left diaphragm peritonectomy or resection as part of their cytoreductive surgery at our institution and were included in the study. The overall median age was 62 years (interquartile range; 52-70) and body mass index 24.9 kg/m2 (interquartile range; 22.1-28.5). Overall, 2.2% (6/267) of patients developed a left diaphragmatic hernia, with 33% (2/6) following a primary cytoreduction and 67% (4/6) following an interval cytoreduction; in addition, 83% (5/6) had a splenectomy at the time of cytoreduction. The median time from date of surgery to time of diagnosis was 12.3 months (range; 4.8-24.8). On univariate analysis, the OR of developing a left diaphragm hernia after undergoing splenectomy was 3.2 (p = .24). Diaphragmatic hernias occurred most often following the setting of concurrent splenectomy; however, splenectomy was not a statistically significant risk factor. These findings provide meaningful insight into the frequency and clinical context in which this complication may arise, addressing a critical knowledge gap in the surgical management of patients with ovarian cancer who require upper abdominal and thoracic procedures.
12 August 2025 in European Journal of Surgical Oncology
Epithelial ovarian cancer remains a leading cause of mortality among gynecological malignancies, with a high incidence of peritoneal carcinomatosis at diagnosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a promising treatment for advanced-stage epithelial ovarian cancer, potentially improving recurrence-free and overall survival rates. The study aimed to investigate the impact of hyperthermia on cisplatin concentrations in healthy abdominal tissues by comparing HIPEC with normothermic intraperitoneal chemotherapy (NIPEC) in a novel porcine model. Sixteen cancer-free pigs underwent cytoreductive surgery followed by either HIPEC or NIPEC, with cisplatin administered intraperitoneally. Microdialysis was used to measure local cisplatin concentrations in various abdominal tissues over a 6-h period. The analysis revealed no statistically significant or clinically relevant difference in cisplatin concentrations between the HIPEC and NIPEC groups. In both groups, cisplatin concentrations were consistently higher in the peritoneum than in other tissues, and plasma levels were significantly lower than those in abdominal tissues. Hyperthermia did not enhance cisplatin's tissue penetration, suggesting that NIPEC may be an effective alternative to HIPEC, particularly for fragile and elderly patients. Future studies should investigate whether hyperthermia improves cisplatin delivery and cytotoxicity in tumor-infiltrated peritoneal tissues.
13 September 2025 in International Journal of Gynecological Cancer
To compare cytoreductive outcomes of 2 published algorithms used to triage patients with ovarian cancer to primary debulking surgery versus diagnostic laparoscopy or neoadjuvant chemotherapy. This prospective comparative study was conducted from August 1, 2021, to January 31, 2025. All patients with suspected advanced ovarian cancer who were eligible for primary debulking surgery on initial evaluation were identified. Imaging was reviewed utilizing a standardized radiology synoptic report. Data from the synoptic report were combined with clinical factors to determine a Resectability Score using 1 of 2 algorithms, Resectability Score 1.0 (RS1.0) and Resectability Score 2.0 (RS2.0). The algorithms include different clinical and radiologic variables; both generate low- and high-risk scores, with high-risk scores indicating a greater likelihood of suboptimal primary debulking surgery. In high-risk cases, laparoscopic evaluation of resectability was recommended, but management was based on surgeon's discretion. Of 237 patients identified, 200 had primary debulking surgery with final pathology confirming epithelial ovarian carcinoma. Of 144 patients (72%) who underwent laparotomy and primary debulking surgery, 110 (76%) were triaged directly to surgery and 34 (24%) first underwent diagnostic laparoscopy; 120 (83%) had complete gross resection, 135 (94%) had residual disease ≤1 cm, and 9 (6%) had residual disease >1 cm. Of 56 patients (28%) who underwent neoadjuvant chemotherapy, 43 (77%) first underwent diagnostic laparoscopy, and 13 (23%) were triaged directly to chemotherapy. Among all patients, 44 (22%) had high-risk scores using RS1.0 and 54 (27%) using RS2.0. RS2.0 more frequently predicted the ability to and inability to achieve complete gross resection (p > .05). RS2.0 more accurately identified high-risk disease warranting neoadjuvant chemotherapy (p = .035). Most surgeons (73%) preferred RS2.0, citing ease of use and faster calculation time. RS2.0 demonstrated favorable predictive accuracy for complete gross resection and was preferred among surgeons. The favorable complete gross resection rate (83%) highlights the value of individualized preoperative triage for primary debulking surgery versus neoadjuvant chemotherapy.